- FDA is the source of guidance for U.S. healthcare providers.
- FDA is the source of guidance for U.S. healthcare providers.
- Eli Lilly and Company operates consistent with guidance provided by the FDA.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
Foghorn's FHD-909 trial advances with Eli Lilly and Company.
3 reports, 2 independent
Updated Oct 15
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Foghorn's FHD-909 trial advances with Eli Lilly and Company.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Eli Lilly ends collaboration on drug program with Foghorn Therapeutics.1 source
Foghorn's FHD-909 trial advances with Lilly.1 source
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company